A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma
- Determine the toxicity of docetaxel and carboplatin in patients with platinum-sensitive
stage III or IV ovarian epithelial or primary peritoneal cavity cancer in first
- Determine the response rates (complete and partial response) in patients treated with
- Determine relapse rates and event-free survival and overall survival rates in patients
treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1.
Patients also receive pegfilgrastim subcutaneously on day 2 . Treatment repeats every 21
days for up to 6 courses.
After completion of study treatment, patients are followed at 3 weeks, every 3 months for 2
years, and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 4-5 years.
Masking: Open Label, Primary Purpose: Treatment
Leona A. Holmberg, MD, PhD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|
|University of Washington School of Medicine||Seattle, Washington 98195|
|Pacific Gynecology Specialists||Seattle, Washington 98104|